|
India’s Biosimilar Guidelines Guarantee Less Clinical Requirements Under Some Conditions
Like with its FDA counterparts, Indian regulators promise fewer clinical trials for biosimilars makers who can prove their product closely matches its reference product, according to new guidelines.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives